This session will inform HCPs on the tirzepatide molecule, the SURMOUNT global trial program for the treatment of obesity and overweight, and the safety and efficacy data disclosure for SURMOUNT-3 and SURMOUNT-4. CME/CE Expiration Date: 4/26/27 *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership · $2,000–3,000/yr
| Individual Course (pay-per-activity) | $21 |
| All Access Pass – OMA Member | $2,000/yr |
| All Access Pass – Non-Member | $3,000/yr |
Collected from the provider’s public pages · source
Specialties served/covered
- Adolescent Medicine
- Cardiovascular Disease
- Child & Adolescent Psychiatry
- Clinical Informatics
- Clinician Wellness & Burnout
- Communication & Shared Decision-Making
- Comprehensive & Board Review
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- General Surgery
- Geriatric Medicine
- Health Equity & Inclusion
- Maternal-Fetal Medicine
- Medical Leadership & Administration
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Nephrology
- Neurodevelopmental Disabilities
- Obstetrics & Gynecology
- Orthopaedic Surgery
- Patient Safety & Quality Improvement
- Physical Medicine & Rehabilitation
- Plastic & Reconstructive Surgery
- Practice Management & Ethics
- Preventive Medicine
- Primary Care Sports Medicine
- Sleep Medicine
- Transplant Hepatology
- Cardio-Vascular
- Cross-Specialty
- GI & Liver
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Orthopedics
- Pediatrics
- Primary care
- Psychiatry
- Rehabilitation
- Sports & Exercise Medicine
- Surgery
- No reviews yet. Be the first to share yours.
Faculty 1
All faculty
- On-demand / recorded video
- Credit · Up to 1 credit
- $25
-
ReleasedApr 29, 2024
-
Last day to claim creditApr 28, 2027 7 months left
-
Obesity Medicine Association Overcoming Obesity 2023 – Safety and Efficacy of Tirzepatide for Chronic Weight Management: SURMOUNT-1 and SURMOUNT-2 (Recorded)
-
Obesity Medicine Association Obesity Medicine 2025 – Opportunity for Shared Decision Making: Tirzepatide for OSA with Obesity (Recorded)
-
Obesity Medicine Association Obesity Medicine 2025 – Investigational Anti-Obesity Drugs in the Pipeline (Recorded)
-
Learner’s Digest International (TM) What to Know About the New Obesity Medications
-
Medvarsity Technologies Private Limited Diabetes Management in the Era of Surging Obesity
-
Medical Letter, The 1765: Influenza Vaccination Recommendations, Tirzepatide for CV Risk Reduction, New Drugs for Breast Cancer, Melanoma, and Hearing Loss
